The US FDA has scheduled an Arthritis Advisory Committee (AAC) meeting for Wednesday, July 13, 2016, to discuss biologics license application 761042, for GP2015 (or GP 2015), a proposed biosimilar to Amgen Inc.’s Enbrel (etanercept) submitted by Sandoz, Inc. (Sandoz), a unit of Novartis AG.
See the SAC Tracker report